The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)” FDA has cleared the IND for intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for human study in mild to moderate Alzheimer’s Disease The publication shows anti-CD3 monoclonal antibody (mAb) administered intranasally, […]
Tiziana Life Sciences announced a late-breaking poster presentation on treating non-active secondary progressive multiple sclerosis with nasal anti-CD3 monoclonal antibody (Foralumab).
Tiziana Life Sciences announced that Matthew Davis, its Chief Operating Officer and Chief Medical Officer, will present at BIO-Europe in Munich, Germany.
Tiziana Life Sciences aims to develop therapies for non-active secondary progressive multiple sclerosis, Alzheimer’s, ALS, and other neuroinflammatory and neurodegenerative conditions.